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ABSTRACT 
SHORR, BRIAN The Impact of State-Level Naloxone Access Policies on Opioid Related 
Mortality and Admissions 
Department of Economics, June 2018 
 
ADVISOR: Professor Jia Gao 
 
Opioids, both prescription painkillers and illegal drugs, were responsible for over 33,000 
deaths in the United States during 2015. Naloxone treatment to combat opioid overdoses has 
been used in hospital settings for decades, and during recent years legislation has expanded 
training and distribution to first aid responders and high risk groups. Several studies have 
projected the efficacy of community-based opioid overdose prevention programs (OOPPs) and 
prescription drug monitoring programs (PDMPs), but few have examined state naloxone access 
policies. This paper investigates the impact of three state policies – non-patient specific 
prescriptions, third-party prescriptions, and layperson legal immunity when administering 
naloxone – on reducing opioid related mortality and treatment admissions. Data is collected from 
the National Center for Health Statistics, SAMHSA, the National Survey of Substance Abuse 
Treatment Services (N-SSATS), Legal Science database, and the Behavior Risk Surveillance 
System. A difference-in-difference method has been adopted. I find that from 1999 until 2017, 
naloxone access policies, especially non-patient specific prescriptions, have increased opioid 
mortality and admissions. Issues of moral hazard and policy endogeneity indicate that these 
results may not be reliable. 
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CHAPTER ONE 
INTRODUCTION 
Drug-related overdose is the leading cause of accidental death in the US and deaths from 
opioid overdose are significant contributors to these statistics, having quadrupled since 1999 
(Public, 2017). According to the Centers for Disease Control and Prevention (CDC), there were 
47,055 lethal drug-related overdoses in 2014, the highest rate of deaths from overdose of any 
year on record. Deaths from opioid overdose accounted for 62% of those fatalities, with 18,893 
overdose deaths related to prescription opioids and 10,574 overdose deaths related to heroin 
(Public, 2017). The US Department of Health and Human Services has recognized opioid related 
overdose as a major public health concern, resulting in more than 33,000 deaths just in 2015 
(Kerensky, Todd, & Walley, 2017). Opioids also cause hundreds of thousands of non-fatal 
overdoses resulting in exorbitant levels of preventable healthcare expenses each year (Legal, 
2017). The economic costs of the heroin and opioid abuse crisis are exorbitantly high, and 
continue to rise yearly. These drug related costs include increased medical care use, worker 
absenteeism, lost productivity, and the direct costs of police enforcement and interdiction 
(Evans, Lieber, & Power, 2018). In addition, there are lost earnings due to mortality. 
This paper explores the effect of three state policies designed to decrease opioid fatalities 
and treatment admissions by promoting greater use and distribution of naloxone medication as 
opposed to restricting the illicit use of opiates. In this paper, a dynamic difference-in-difference 
(DD) model is used to evaluate opioid related mortality rate and treatment admission trends over 
time and between states. I hypothesize that the adoption of naloxone non-patient specific 
prescription, third-party prescription, and Good Samaritan policies will result in decreasing 
trends of opioid related mortality and treatment admissions. I also expect a delay or lag in the 
effects of the increased naloxone access policies. Once a policy has been enacted it will take time 
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to produce elevated quantities of naloxone, distribute it to newly legalized customers, and train 
these individuals to properly use the application device. To study this question, I use annual state 
opioid mortality data from National Center for Health Statistics and opioid treatment admissions 
data from the National Survey of Substance Abuse Treatment Services (N-SSATS). I find that 
the adoption of naloxone access policies, have increased average state opioid mortality and 
admissions, which is opposite to their intended purpose.  
This paper seeks to contribute to existing literature by exploring the efficacy of state-
level naloxone access policies on opioid mortality and admission outcomes. The content of this 
paper can potentially help identify the most effective state legislation for preventing opioid 
overdose and abuse.  It will provide vital information to policy makers and government bodies, 
which will allow them to better allocate funds towards efforts that will be most beneficial to 
reducing negative opioid outcomes. 
The next chapter of this paper provides background information regarding economic 
factors which affect opioid outcomes and information about the clinical effectiveness of 
naloxone medication. It also provides an explanation of each of the major policies that will be 
discussed in this paper. Chapter three reviews literature on community programs and previous 
legislation designed to limit opioid abuse. A description of the data and empirical methods are 
presented in chapters four and five respectively. The results are analyzed in section six, with a 
conclusion presented in chapter seven. 
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CHAPTER TWO 
BACKGROUND 
Physical health has declined in recent years coinciding with increases in drug poisoning 
deaths, often involving opioid analgesics including hydrocodone and oxycodone. Understanding 
the relationship between local economic conditions and drug-related adverse outcomes is 
important because the United States is experiencing an epidemic of drug overdose fatalities 
(Hollingsworth, Ruhm, & Simon, 2017). According to Hollingsworth et al. there is strong 
evidence that suggests opioid related deaths and emergency department (ED) visits increase 
during times of economic weakness (2017). Increased availability of prescription opioids and 
reductions in heroin prices, have created a path of increased drug consumption when economic 
conditions deteriorate because people attempt to comfort themselves through increased drug 
abuse. ED visits involving narcotic pain relievers increased 117% between 2005 and 2011, and 
opioid related ED visits grew by 39.5% from 2006 to 2014. Trends of elevated opioid deaths and 
ED visits were observed during periods of increased national unemployment rate. These results 
indicate that a one percentage point increase in the unemployment rate will raise predicted opioid 
mortality rates by 0.19 per 100,000 people. 
Opioid tolerance, dependence, and addiction are all manifestations of brain changes 
resulting from chronic opioid abuse. The opioid abuser’s struggle for recovery is in great part a 
struggle to overcome the effects of these changes. Brain abnormalities resulting from chronic use 
of heroin, oxycodone, and other morphine-derived drugs are underlying causes of opioid 
dependence and addiction (Kosten, Thomas, & George, 2002). Opioids attach to specialized 
proteins, called mu opioid receptors, on the surfaces of opiate-sensitive neurons. The linkage of 
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these chemicals with the receptors triggers the same biochemical brain processes that reward 
people with feelings of pleasure (Kosten, Thomas, & George, 2002). 
Repeated exposure to escalating doses of opioids alters the brain so that it functions more 
or less normally when the drugs are present and abnormally when they are absent. Two clinically 
important results of this alteration are opioid tolerance (the need to take higher and higher 
dosages of drugs to achieve the same opioid effect) and drug dependence (susceptibility to 
withdrawal symptoms) (Kosten, Thomas, & George, 2002). Opioid tolerance occurs because 
brain cells with opioid receptors gradually become less responsive to opioid stimulation. In the 
presence of excessive opioids, these cells will reduce the number of mu opioid receptors and 
require higher doses of the drug to receive the same physiological response (Kosten, Thomas, & 
George, 2002). 
Naloxone’s effectiveness as a mu-opioid antagonists and its ability to reverse opioid 
overdoses is well established in clinical research. Ling, Amass, Shoptaw, Annon, Hillhouse, 
Babcock, & Brigham (2005) conducted a multicenter randomized trial to investigate and 
compare the clinical effectiveness of buprenorphine–naloxone (bup‐nx) to alternative clonidine 
treatments for opioid detoxification in inpatient and outpatient community treatment programs. A 
total of 59 of the 77 (77%) inpatients assigned to the bup‐nx condition achieved treatment 
success criterion compared to eight of the 36 (22%) assigned to clonidine (Ling et al, 2005). 
Additionally, 46 of the 157 (29%) out‐patients assigned to the bup‐nx condition achieved 
treatment success criterion, compared to four of the 74 (5%) assigned to clonidine (Ling et al, 
2005). This research provides evidence in support of naloxone use for opioid detoxification. 
Although several states still consider naloxone to be a prescription drug, it is not a 
controlled substance and does not have abuse potential. It is regularly utilized by medical first 
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responders and can be administered by ordinary citizens with little or no formal training (Legal, 
2017). Despite the overwhelming benefits to its use, naloxone is often not available when and 
where it is needed. Opioid overdoses most often occur when the victim is with friends or family 
members, but in many cases neither the victim nor his or her companions have the medication on 
hand. Legal restrictions are at least partially responsible for this lack of access. Several state 
practice laws prohibit the prescription of naloxone to a person other than the one to whom 
treatment will be administered. Many states also prevent pharmacies and physicians from 
distributing naloxone to any individuals with whom the prescriber does not have a prescriber-
patient relationship (Legal, 2017). Many medical professionals are wary of dispensing naloxone 
because of fears of misuse and liability consequences. Compounding this issue, people who 
witness an overdose may be afraid to call for help due to concerns of being prosecuted for 
possession of illegal drugs, drug paraphernalia, or other crimes (Legal, 2017).  
Naloxone will be most effective when placed in the hands of those individuals most 
likely to respond to an overdose. New naloxone access laws have simplified the process for 
obtaining naloxone. These updated laws have expanded naloxone availability and decreased 
restrictions on those who can purchase, distribute, and administer the drug (Public, 2017). An 
increasing number of states have allowed third-party prescriptions – permitting naloxone to be 
issued to third parties, who are not at risk of overdose, for use on someone else. These include 
close friends of at risk individuals, family members, and professionals working with at risk 
populations (Naloxone Access, 2018). Nearly all states have also established legal protections for 
those who distribute, carry, or administer naloxone as permitted by law. These Good Samaritan 
laws provide laypersons immunity from civil and criminal liability when administering naloxone 
(Naloxone Access, 2018). Many states have authorized non-patient specific prescriptions 
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allowing individuals and organizations that meet specific criteria to purchase naloxone without 
needing to interact with a prescriber beforehand (Naloxone Access, 2018). A variety of models 
have emerged for non-patient specific prescriptions, but from the viewpoint of the patient these 
different types of programs are largely non-distinguishable. 
As of 2016, fourteen states have made naloxone available over the counter at pharmacies 
for individuals vulnerable to opioid overdose or members of their families, significant others, or 
companions. By July 15, 2017, all fifty states and the District of Columbia had passed legislation 
designed to improve layperson naloxone access. Forty states and the District of Columbia have 
also passed Good Samaritan laws that provide some protection from arrest or prosecution for 
individuals who treat or report an overdose (Legal, 2017). In most cases, considerable 
educational material and training have been developed for each respective program to ensure that 
those who administer naloxone in response to an overdose are adequately prepared for safe and 
effective administration. In 2014, it was reported that more than 150,000 laypersons had received 
naloxone training and rescue kits resulting in more than 26,000 reported overdose reversals 
(Public, 2017). Studies have found that increasing access to naloxone among people who use 
drugs is associated with decreases in overdose deaths and that there is no associated increase in 
the use of opioids or other addictive substances (Public, 2017). 
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CHAPTER THREE 
LITERATURE REVIEW 
 There has been an ample amount of research regarding the effectiveness of local 
community programs that deal with overdose prevention and naloxone utilization. These 
facilities train individuals to perform proper overdose treatment protocols and help increase the 
distribution of naloxone within high risk communities. These community programs have been 
extremely successful, but many struggle to promote contact of emergency medical services 
(EMS) in the event of an opioid overdose. The fear of legal ramifications has been cited as the 
primary reason for not calling EMS. Researchers have also examined the impact of state and 
federal policies which have altered access to opioid prescriptions. Prescription drug monitoring 
programs and doctor shopping laws have been shown to greatly reduce opioid related mortality 
rates, but other policies such as Medicare part D have had unintentional effects resulting in 
greater opioid abuse. Despite its ability to reverse opioid overdoses in both inpatient and non-
clinical settings, little research has been completed to investigate the potential benefits of state 
policies designed to increase access to naloxone. Initial evidence suggests that state naloxone 
access policies may be able to reduce opioid related mortality by as much as 11%, but additional 
research is required to confirm these findings. 
A: Overdose Prevention and Naloxone Distribution Community Programs 
Although naloxone is a highly effective drug, to achieve the best outcomes, it must be 
used appropriately in combination with other life saving interventions. Various community 
programs have been designed to educate people about proper naloxone use and overdose 
treatment protocols. Despite these efforts to educate people, there have been many cases in 
which bystanders did not administer naloxone or call EMS after witnessing an opioid overdose 
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because they feared legal repercussions. Clark, Wilder, and Winstanely (2014) conducted a 
systematic review of nineteen community opioid overdose prevention and naloxone distribution 
programs (OOPPs). The researchers’ analysis of existing nonrandomized studies suggests that 
bystanders, especially opioid users, will use naloxone to reverse opioid overdoses when properly 
trained, and OOPP is effective in addressing opioid abuse. It has been recognized that most 
OOPP participants do not call EMS when they witness an overdose. Additional research has 
been suggested to investigate whether laws that provide civil and criminal protection for 
bystanders would result in increased notification of EMS during an overdose occurrence. 
To evaluate the effectiveness of these community education programs Strang, Manning, 
& Mayet (2008) examined the impact of OOPP training on the knowledge and confidence of 
opiate users in managing overdoses. The researchers noted statistically significant improvements 
in knowledge of risk factors for overdose, overdose signs, appropriate responses to overdose, and 
use of naloxone immediately after OOPP training. Three months after the initial training, 78% of 
participants demonstrated retention of overdose management knowledge. These overdose 
management programs can train opiate users to execute appropriate actions to assist the 
successful reversal of a potentially fatal overdose. The researchers suggest future studies that 
examine whether public policy of wider overdose management training and naloxone provision 
could reduce the extent of opiate overdose fatalities, particularly at times of recognized increased 
risk. 
B: Opioid Prescription Policies 
Federal, state, and local governments have enacted a range of policies designed to combat 
nonmedical use of prescription opioids. The most common and well-studied policy is the 
mandatory use of prescription drug monitoring programs (PDMPs). Such programs require retail 
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pharmacists to enter information about controlled substance prescriptions and recipients into an 
electronic database within a specific period of time, typically 7 to 14 days (Popovici, Maclean, 
Hijazi, & Radakrishnan, 2018). Healthcare providers can access this database to determine if a 
patient is engaging in doctor shopping behavior – visiting several physicians to obtain multiple 
prescriptions for otherwise illegal drugs. Numerous studies suggest that PDMPs have been the 
best deterrent in the attempt to reduce prescription opioid abuse. Evidence on the effectiveness of 
other laws designed to address nonmedical use of prescription opioids is limited (Popovici et al., 
2018). 
Healthcare providers who regularly conspire in the dispensing of prescription opioids 
outside the scope of prevailing medical standards or in violation of state laws are viewed by 
policymakers as a key contributing factor to the prescription opioid epidemic (Popovici et al., 
2018). Nine states have enacted pain management clinic laws with the objective of reducing 
providers' ability to prescribe opioids for use beyond acceptable medical standards. Popovici et 
al. (2018) used a difference‐in‐difference (DD) regression model to study the effect of pain 
management clinic and doctor shopping laws on state opioid outcomes. On average, pain 
management clinic laws reduced prescription opioid overdose deaths by 9.6%, doctor shopping 
law reduced prescription opioid overdose deaths by 8.5%, and the implementation of a PDMP 
programs reduced prescription opioid overdose deaths by 4.8%. 
Opioids have legitimate medical functions, but improving access to these potentially 
deadly drugs may increase abuse rates. Powell, Pacula, and Taylor (2015) used the Treatment 
Episode Data Set (TEDS) to study annual opioid abuse treatment admissions by state following 
the implementation of Medicare Part D. The researchers’ estimates imply that a 10% increase in 
medical opioid distribution through Medicare Part D lead to a 7.4% increase in opioid related 
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deaths and a 14.1% increase in treatment admission rates for the Medicare-ineligible populations 
(Powell et al., 2015). Medicare Part D increased opioid utilization for the 65+ population. This 
increase in utilization led to significant growth in the overall supply of opioids in high elderly 
share states relative to low elderly share states, but the expansion in opioid supply through 
Medicare Part D also resulted in an escalation in opioid related treatment admissions and opioid 
related mortality among the Medicare-ineligible population. This implies that increases in opioid 
distribution through Medicare Part D may be causing a spillover of these drugs into populations 
that are not Medicare beneficiaries and an increased diversion of prescription opioids for 
nonmedical purposes. 
C: Impact of OxyContin Reformulation 
Evans, Lieber, & Power (2018) examined how changes to the reformulation of OxyContin 
impacted the subsequent rise in heroine abuse and mortality rates. The paper shows that between 
1999 and 2009, opioid death rates were rising rapidly but heroin death rates were much lower 
and increasing slowly. Between 2010 and 2014, heroin death rates increased by a factor of four 
while opioid death rates remained fairly flat. The researchers attributed this rapid rise in the 
heroin mortality rates to the 2010 reformulation of OxyContin. The makers of OxyContin, 
Purdue Pharmaceutical, removed the existing drug from the market and replaced it with an 
abuse-deterrent formulation (ADF) that made it more difficult for the drug to be abused. This 
made the drug far less appealing to opioid addicts and led many to shift to heroin as a potent 
substitute that was readily available and cheaper in cost. Heroin deaths began rising during the 
month following the distribution of the reformulated drug. The reformulation did not generate a 
reduction in combined heroin and opioid mortality because each prevented prescription opioid 
death was replaced with a heroin casualty. Efforts to restrict opioid prescriptions may not 
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decrease opiate overdose and mortality because abusers will turn to heroine as an affordable 
alternative. Legislators should focus on improving opioid treatment, prevention, and access to 
naloxone as these are likely the best means to counteract overdoses. 
D: Naloxone Access Policies 
In an effort to address the opioid epidemic, the majority of states have recently passed 
some version of a naloxone access law (NAL) or a Good Samaritan law (GSL). The study 
conducted by Rees, Sabia, Latshaw, & Dave (2017) is the first to examine the effect of these 
NALs and GSLs on opioid related casualties. The researchers utilized a difference-in-difference 
model to examine temporal and geographic variation in the passage of NALs and GSLs to gain a 
better understanding of their effects. Using data from the National Vital Statistics System 
multiple cause-of-death mortality files for the period 1999-2014, the researchers have found that 
the adoption of a NAL is associated with a 9 to 11 percent reduction in opioid related fatalities. 
The estimated effect of GSL on opioid related deaths is of comparable magnitude, but not 
statistically significant at conventional levels (Rees et al., 2017). The relationship between NALs 
and opioid related deaths that do not involve heroin appears to be stronger than the relationship 
between NALs and heroin related deaths. This indicates that NALs are more effective at 
preventing overdoses from prescription opioid painkillers than illicit drugs. Critics and 
supporters of the laws debate whether NALs and GSLs benefit drug users and reduce mortality 
rates. Many believe they will promote greater drug use, but the researchers have discovered little 
evidence to suggest that these laws increase the recreational use of prescription painkillers (Rees 
et al., 2017). 
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CHAPTER FOUR 
DATA 
A: Outcome Measurements 
In order to assess the issue of opioid abuse and misuse, I focus on two broad measures of 
opioid related outcomes: treatment admissions (2002–2017) and state-level overdose mortality 
from opioid medications (1999–2017). Due to the recent rise in heroin use, particularly in 
response to a 2010 reformulation of OxyContin, I am considering treatment admissions and 
overdose mortality for a combined category of heroin and prescription opioids, which together 
will be referred to as opiates. All data variables are measured by state and year. Washington D.C. 
has also been included in the analysis of each state. 
Opioid related mortality is measured as the number of annual deaths from prescription 
opioids and heroine per 100,000 populations. The second dependent variable is the number of 
opioid related treatment admissions by state and year per 100,000 populations. Opioid related 
mortality from 1999 to 2017 is obtained from the National Center for Health Statistics. My focus 
is on estimating the impact of  NALs and GSLs on drug overdose deaths involving opioids 
identified and defined by the International Classification of Diseases, Tenth Revision multiple-
cause-of-death codes: T40.0 (opium), T40.1 (heroin), T40.2 (other opioids), T40.3 (methadone), 
T40.4 (other synthetic narcotics), and T40.6 (other unspecified narcotics). This is useful for 
creating operational definitions for measurements of opioid related mortality rates. It should be 
noted that the ICD-10 defines the term “narcotic” to include both cocaine derivatives and 
opioids, so that some portion of the deaths identified by the multiple cause-of-death code T40.6 
could have been caused by cocaine. Deaths from cocaine use represent only a small fraction of 
total opioid related fatalities. A total of 29,650 opioid related deaths occurred in the United 
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States in 2014, but only 1,635 (5.5 percent) involved unspecified narcotics and no other type of 
opioid (National, 2017). 
Mortality rates due to drug overdoses are reported per 100,000 population and are based 
on April 1
st
 bridged-race census counts for 2000 and 2010, on July 1
st
 bridged-race estimates for 
1999 and 2001–2009, and on vintage 2015 post census estimates for 2011–2017. From 1999 to 
2017, almost 218,000 people died in the United States from overdoses related to prescription 
opioids. Overdose deaths involving prescription opioids were five times higher in 2017 than in 
1999 (Wide-ranging, 2016). Mortality rates from prescription opioids were highest in the states 
of West Virginia, Maryland, Kentucky, and Utah (Scholl et al., 2018). 
Opioid related treatment admissions data from 2002 to 2017 was obtained from the 
National Survey of Substance Abuse Treatment Services (N-SSATS), which is an annual survey 
of facilities providing substance abuse treatment conducted by the Substance Abuse and Mental 
Health Services Administration (SAMHSA). The N-SSATS collects data on the location, 
characteristics, services offered, and number of clients in treatment at alcohol and drug abuse 
treatment facilities. My interests are in estimating the effects of non-patient prescription, third-
party prescription, and Good Samaritan laws on opioid related treatment admissions throughout 
the 50 states and the District of Columbia. 
B: Data Summary 
From 1999 to 2017 an average of 7.925 ± 5.484 per 100,000 people living in the US died 
from opioid overdose or other opioid related complications. In 2017, West Virginia had the 
highest recorded state opioid related mortality rate at 45.873 deaths per 100,000 people living in 
the state. Conversely, 1999 Iowa had the lowest recorded state opioid related mortality rate at 
0.514 deaths per 100,000 people. 
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Annual admissions rates to opioid treatment programs also tend to vary greatly from state 
to state as well as year to year. During the period from 2002 to 2017 – excluding 2014 – the 
national average for opioid related admission was 115.224 ± 103.609 patient admissions per 
100,000 people. State treatment admission rates were highest in 2015 Rhode Island. 715.208 
people per 100,000 population in Rhode Island were admitted for opioid overdose or related 
complications. In 2013, South Dakota had the lowest admission rates of 0.119 people per 
100,000 population. 
Between 1999 and 2017, several states enacted legislation with the intent to reduce opioid 
related admissions and mortality. Previous studies have examined the effects of prescription drug 
monitoring programs (PDMP) and pain management clinic laws (PMCL) on opioid abuse 
outcomes. Implementation of these laws has resulted in a significant reduction in opioid related 
admission and mortality rates for many states. Between 1999 and 2017 an average of 68.717% 
and 7.904% of states had passed PDMP and PMCL legislation respectively. By 2014, every state 
with the exception of Missouri required physicians and pharmacies to participate in prescription 
drug monitoring programs. It is important to note that there have been rumors that Missouri’s 
state legislators will propose a plan to implement its own statewide drug monitoring program by 
the end of 2019 (Hauswirth, 2018). 
Little is currently known about the effects of legislation designed to promote naloxone 
use and accessibility. Non-patient specific prescription laws (NPL), third-party prescription laws 
(TPL), and Good Samaritan laws (GSL) are meant to increase naloxone availability with the 
hope that this will reduce the number of preventable admissions and deaths due to opioid 
overdose. On average, between 1999 and 2017, 18% of states had implemented NPLs, 22.401% 
of states had implemented TPLs, and 19.365% of states had implemented GSLs. Illinois was the 
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earliest adopter of NPLs, and the second adopter of TPLs as well as GSLs in 2010. New Mexico 
was the earliest adopter of TPLs and GSLs in 2001. 
All state-year-level demographic controls were obtained from the CDC’s BRFSS 
database including statistics for age, gender, race, education level, employment, income level, 
marital status, smoking status, and binge drinking. This evaluation was conducted with a test 
group between the ages of 18 and 65. All individuals below the age of 18 or above the age of 65 
have been excluded. Between 1999 and 2017, approximately 6.435% of the US population was 
between the ages of 18 and 24, 17.460% of the population was between the ages of 25 and 34, 
22.709% of the population was between the ages of 35 and 44, 27.108% of the population was 
between the ages of 45 and 54, and 26.288% of the population was between the ages of 55 and 
64. On average, 47.061% of the US population was male and 81.869% was white. On average, 
44.588% of people had a bachelor’s or advanced degree in higher education, 28.025% of people 
had some college education, 23.156% had a high school education, and 11.625% did not 
complete high school. The average unemployment rate between 1999 and 2017 was 5.044%. On 
average, 77.861% of the population was employed and the remaining 17.095% was not 
considered part of the labor force. On average, only 38.859% of households earned more than 
$75,000 each year while more than 17% of households had an annual income less than $25,000. 
Approximately 17% of US households would be in poverty based on the 2019 poverty line, 
which sets the poverty level at  $25,750 annual income for a four person household (2019 
Poverty, 2019). 59.314% of people were married and 19.174% were divorced.  On average, 
21.617% of the US population smoked and 10.928% binge drank within the last 30 days. 
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CHAPTER FIVE 
EMPIRICAL MODEL 
Independent variables are broken down into three categories: naloxone policies of 
interest, other policy controls, and demographic characteristics. The Legal Science dataset 
provides details on state policies regarding naloxone administration and overdose prevention. For 
the purpose of this paper, I am interested in evaluating the effects of three specific policies on 
opioid related mortality and treatment admission outcomes. I use a series of dummy variables to 
indicate whether a state allows prescriptions of naloxone to third-parties, whether pharmacists 
are allowed to dispense or distribute naloxone without a patient-specific prescription from 
another medical professional, and whether a layperson is immune from criminal liability when 
administering naloxone. If a state has a law allowing one of these policies in year “t” then the 
respective dummy variable will receive a value of one. If a law allowing a policy has not been 
enacted in year “t” then the dummy variable for state “s” in year “t” will receive a value of zero.  
Other control policies include PDMP must access laws and pain management clinic laws 
(PMCL). If physicians are required to access PDMP records before writing a prescription for an 
opioid in state s and year t then the PDMP dummy variable will be one. Otherwise the variable 
will be zero. Similarly states with PMCL policies in year t will have a dummy variable of one 
while states without PMCL policies will have a dummy variable of zero. 
In this paper, a dynamic difference-in-difference (DD) model is used to evaluate temporal 
and geographic variation in the passage of NALs and GSLs to gain a better understanding of 
their effects on opioid related mortality rate and treatment admission. Specifically, we estimate 
the following baseline Poisson regression: 
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(1)  Yst = β0+β1*NPLst+β2*TPLst+β3*GSLst+β*Xst+θs+τt+Ωst+ϵst 
 
where Yst represents an opioid outcome – either the expected number of opioid related deaths or 
the expected number of opioid related treatment admissions in state s and year t. The 
independent variables of interest are NPLst, TPLst, and GSLst where NPLst is a dummy variable 
equal to one if a non-patient specific prescription law was in effect in state s and year t and equal 
to zero otherwise. The indicators TPLst and GSLst are defined analogously for third-party 
prescription and Good Samaritan laws respectively. The inclusion of state fixed effects, 
represented by the term θs, ensures that the estimates of β1, β2, and β3 are identified using within-
state variation. The year fixed effects, represented by τt, account for common shocks to the 
opioid related deaths caused by such factors as the reformulation of OxyContin in 2010 or 
changes in drug enforcement priorities at the federal level. State‐specific linear time trends (Ωst) 
are also used to control for time‐varying, unobservable state characteristics. I interact state fixed 
effect with a linear time trend that takes on a value of one for 2002, two for 2003, and so forth. εst 
is the error term. 
In subsequent regressions, policy and demographic indicators are added to the vector of 
state characteristics, Xst. Policy indicators such as PDMP and PMCL are equal to one if there is a 
relevant law operating in state s and year t. There is reasonably strong evidence that the 
implementation of a PDMP and PMCL reduces opioid prescriptions and drug treatment 
admissions (Haegerich et al. 2014; Bao et al. 2016). Although, the evidence with regard to 
PDMPs and opioid related deaths is decidedly mixed (Johnson et al. 2011; Reifler et al. 2012). 
Xst also includes demographic controls including age, sex, race, education, and marital status 
taken from the Behavioral Risk Factor Surveillance System (BRFSS). 
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CHAPTER SIX 
RESULTS 
A: Sample Analysis – Opioid Overdose Mortality 
  The beta-coefficients for the NPLst, TPLst, and GSLst dummy variables indicate the 
average change in opioid related mortality per 100,000 people in state s at year t when the law 
has been enacted within the state. It was expected that states with non-patient prescription (NPL), 
third-party prescription (TPL), and Good Samaritan laws (GSL) would experience lower average 
opioid mortality rates. Table 2 presents the results on opioid related mortality using the full 
sample. As shown in Column 1, none of these policies have any effect on opioid mortality. In 
Column 2, I exclude the control for smoking and binge drinking because they might be one of 
the mechanisms in which these policies affect opioid mortality. I find that the results are similar 
to Column1 – none of the policies have any effect on opioid related mortality.  
 States that passed an NPL were also very likely to have passed TPL and GSL legislation. 
Columns 3, 4, and 5 examined the impacts of each policy variable separately due to concerns of 
high levels of multicollinearity (Table 2). Columns 3 and 4 indicate non-patient specific 
prescription and third-party prescription policies increased mortality, but Column 5 indicates that 
Good Samaritan policies did not significantly impact opioid mortality rates. On average, NPLs 
increased a state’s opioid related mortality rate by 1.869 ± 0.884 people per 100,000 population 
(p-value < 0.05). On average, TPLs increased a state’s opioid related mortality rate by 1.321 ± 
0.660 people per 100,000 population (p-value < 0.1). 
B: Sample Analysis – Opioid Related Treatment Admissions 
Table 3, Columns 1 to 6  contain beta-coefficients for the NPLst, TPLst, and GSLst dummy 
variables, which indicate the average change in opioid related treatment admissions per 100,000 
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people in state s at year t when the law has been enacted within the state. It was expected that 
states with non-patient prescription (NPL), third-party prescription (TPL), and Good Samaritan 
laws (GSL) would experience lower average opioid admission rates. According to the Column 1 
results, states which enacted the NPLs experienced a significant increase in opioid admission 
rates. On average non-patient specific prescription laws increased a state’s opioid related 
treatment admissions by 33.137 ± 14.682 admissions per 100,000 people (p-value < 0.05). 
Changes due to TPL and GSL legislation were not statistically significant (Table 3, Column 1).  
 Column 2 examines the impact of smoking and binge drinking on opioid admission rates. 
As with mortality, removal of the smoker and binge_drink variables did not significantly alter the 
beta-coefficients or the standard error for any of the policy variables of interest. Multicollinearity 
between NPLst, TPLst, and GSLst is an issue for predicting admission as well as mortality 
outcomes.  Columns 3, 4, and 5 contain results for regressions when NPLst, TPLst, and GSLst are 
separated (Table 3). In Column 3, non-patient specific prescription laws increased a state’s 
opioid related treatment admissions by an average of 29.246 ± 15.096 admissions per 100,000 
people (p-value < 0.1). Separating the three policies lowered the NPLst beta-coefficient and its 
significance level (Table 3, Column 3). Changes due to TPL and GSL legislation were still 
statistically insignificant (Table 3, Columns 4 and 5). 
C: Subsample Analysis – Opioid Overdose Mortality and Treatment Admissions 
While the initial results may not have been very substantial or significant for the sample 
population, it is possible that NPL, TPL, and GSL could have a greater impact on specific groups 
within the sample. Age, income, and education status are all potential factors which may 
influence the effectiveness of naloxone access policies. The rates of drug overdose deaths have 
increased from 1999 to 2017 for all age groups studied, but adults age 35-44 and 45-54 
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demonstrated significantly higher rates of drug overdose fatalities than any other age group 
(Figure 1). Individuals age 35-54 are more likely to die from an opioid overdose than any other 
age group. These individuals are also most likely to receive the maximum benefit from increased 
naloxone access. Analyzing and comparing the results presented in Table 4, Columns 1 to 6 
indicate that the effects of NPL, TPL, and GSL on opioid related mortality are very similar to 
those presented in Table2, Columns 3 to 5. Changes in opioid mortality rates in response to 
naloxone access policies do not significantly vary between the various age groups. 
There is strong evidence that suggests opioid related deaths and ED visits increase during 
times of economic weakness (Hollingsworth et al., 2017). While research has mainly focused on 
the relationship between opioid overdose and unemployment rate trends, it is possible that low 
income groups may also be highly susceptible to opioid overdose as well as benefit more from 
naloxone access policies. Table 5, Columns 1 to 3, examines the impact of NPLs, TPLs, and 
GSLs for a subsample of households with an annual income less than $25,000. The results for 
low income households do not meet expectations as they are very similar to those for the whole 
sample population. Table 5 results suggest that income level will not impact changes in opioid 
mortality rates in response to naloxone access policies. 
Studies focusing on trends in the 1990s and 2000s highlight stagnating life expectancy 
gains among less educated subgroups, particularly for non-Hispanic white women, and continued 
improvements among more educated subgroups (Ho, 2017). Increasing disparities in life 
expectancy gains among the less educated coincided with the rise of opioid overdose mortality 
that initiated in the late 1990’s, following FDA approval of the opioid pain reliever OxyContin. 
Among college graduates, drug overdose death rates have increased over time, but in the most 
recent period they are still lower than rates observed in the first recorded period for the least 
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educated (Ho, 2017). Education level may play a role in estimating potential risk to opioid 
overdose. Lower education groups may be more likely to overdose, but these subgroups may also 
receive greater benefit from NPL, TPL, and GSL policies. Table 5, Columns 4 to 6, examine the 
impact of NPL, TPL, and GSL for a subsample of individuals with less than a bachelor’s level of 
education. The results are very similar to those for the whole sample population. These results 
suggest that education level likely does not impact the effect of naloxone access policies on 
opioid mortality rates. 
A complete subsample analysis was conducted for opioid mortality outcomes to access 
whether specific subgroups within the sample population would respond differently to NPL, 
TPL, and GSL policies resulting in improved mortality outcomes. A similar analysis was 
completed for opioid related treatment admissions, but no significant changes in the impacts of 
naloxone access policies were observed. To see the results of this analysis please refer to Tables 
6 and 7, Columns 1 to 6. 
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CHAPTER SEVEN 
DISCUSSION 
A: Multicollinearity 
A key goal of regression analysis is to isolate the relationship between each independent 
variable and the dependent variable. The interpretation of a regression coefficient is that it 
represents the mean change in the dependent variable for each one unit change in an independent 
variable when all of the other factors are held constant. The idea is to be able to change the value 
of one independent variable and not the others to observe direct effects of each independent 
variable on the one that is dependant. However, when independent variables are correlated, it 
indicates that changes in one are associated with shifts in another. This is known as 
multicollinearity. The stronger the correlation, the more difficult it is to change one variable 
without changing another. Multicollinearity makes it difficult for a model to estimate the 
relationship between each independent variable and the dependent variable separately because 
the independent variables tend to change in unison. 
Multicollinearity causes coefficient estimates to change drastically based on which 
independent variables are included in the model, and the coefficients become very sensitive to 
small changes. Multicollinearity also reduces the precision of the estimate coefficients, which 
weakens the statistical power of the regression model. Due to the multicollinearity which exists 
between NPLst, TPLst, and GSLst policy variables, it is difficult to trust p-values to identify results 
that are statistically significant. States that have adopted one of the naloxone access policies are 
very likely to adopt the other policies. This makes it extremely difficult to determine whether the 
observed coefficients for NPLst, TPLst, and GSLst are the result of adopting each specific policy 
or the combined effect of multiple policies. 
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B: Moral Hazard and Endogeneity 
 States that have adopted any combination of the non-patient specific prescription, third-
party prescription, or Good Samaritan laws for naloxone were expected to experience reduced 
opioid overdose mortality rates and encounter fewer opioid related treatment admissions. While 
these laws have reportedly increased naloxone availability, my results indicate that NPL and TPL 
laws have also increased the average number of opioid related mortalities (Table 2). States which 
have adopted NPLs have also experienced increases in opioid treatment admissions (Table 5). It 
is strange that these laws designed to improve opioid outcomes would have such negative effects 
on the substance abuser population. 
 Two possibilities exist which could explain these unexpected results. First, increased 
access to naloxone due to adoption of these policies could have encouraged greater opioid abuse, 
resulting in additional opioid related admissions and fatalities. As naloxone became more widely 
available in each state, the immediate risk associated with opioid abuse would be lowered 
causing greater recreational use of prescription medications and illicit drugs. Increased access to 
naloxone may have created a moral hazard situation, in which the extra level of safety provided 
by naloxone promoted increased risky behavior with opioid drugs. This scenario is not very 
likely because if a naloxone moral hazard existed significant increases in mortality and 
admissions would be associated with all three policy variables – not only NPL. 
 There is also a possibility that states with high levels of opioid fatalities and admissions 
are much more likely to adopt naloxone access policies than states with lower previous mortality 
and admission rates. This would create an endogeneity issue in which a state’s opioid related 
mortality or admissions for the previous year are highly correlated with the independent policy 
variable for the current year. In this way, states that have a history of high mortality or 
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admissions will be more likely to adopt NPL, TPL, or GSL policies. This will affect future 
mortality and admission rates, which will ultimately affect the continued use or adoption of 
future policies. In order to evaluate potential issues of endogeneity, I estimate the following 
equation: NPLst = β0+β1* Y_lagst + ϵst, where NPLst is a measure of the probability that state s 
will adopt a non-patient specific prescription law in the year t. Y_lagst represents an opioid 
outcome – either mortality or treatment admissions – in state s and the year t-1. I find that the 
previous year’s opioid overdose mortality and treatment admissions are significantly correlated 
with the current year’s NPLst, which indicates that the adoption of non-patient specific 
prescription policies is non-random. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25 
 
CHAPTER EIGHT 
CONCLUSION 
Significant research has determined that the adoption of NPLs and TPLs is associated 
with a 9 to 11 percent reduction in opioid overdose mortality. The estimated effect of GSL on 
opioid related deaths is of comparable magnitude, but not statistically significant at conventional 
levels (Rees et al., 2017). The relationship between naloxone access policies (NALs) and opioid 
related deaths that do not involve heroin appears to be stronger than the relationship between 
NALs and heroin-related deaths. This indicates that NALs may be more effective at preventing 
overdoses from prescription opioid painkillers than illicit drugs. Critics and supporters of the 
laws debate whether NALs benefit drug users or reduce mortality rates. Many believe increased 
accessibility to naloxone will promote greater recreational opiate use, but these concerns pale in 
comparison to the potential benefit of increased naloxone access (Rees et al., 2017). NAL 
policies are expected to greatly reduce the number of opioid related deaths, and prevent 
avoidable opioid related treatment admissions to healthcare facilities. This should assist in 
reducing medical care expenses within the United States.  
Upon review of available analytics, I have determine that the efforts of state legislators to 
reduce opioid abuse within the United States during the last nineteen years have at best been a 
deterrent but have not been effective in ending the opioid crisis. In contrast to policy 
expectations, non-patient specific prescription laws resulted in significant increases in both 
opioid related mortality and treatment admissions, but third-party prescription and Good 
Samaritan laws did not have any significant effect on opioid outcomes. In addition, subsample 
analysis did not reveal significant variation in the impact of state naloxone access policies 
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between high opioid risk subgroups and the full sample population. It should be noted that issues 
of moral hazard and policy endogeneity indicate that these results may not be reliable. 
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Table 1. Data Summary 
Variable Obs Mean Std. Dev. Min Max 
mortality 2,251,323 7.925 5.484 0.514 45.874 
admissions 1,876,978 115.224 103.609 0.119 715.208 
year 2,269,061 200920.200% 4.951 1999 2017 
npl 2,269,061 18.000% 0.384 0 1 
tpl 2,269,061 22.401% 0.417 0 1 
gsl 2,269,061 19.365% 0.395 0 1 
pdmp 2,212,447 68.717% 0.464 0 1 
pmcl 2,269,061 7.904% 0.270 0 1 
age_18to24 2,269,061 6.435% 0.245 0 1 
age_25to34 2,269,061 17.460% 0.380 0 1 
age_35to44 2,269,061 22.709% 0.419 0 1 
age_45to54 2,269,061 27.108% 0.445 0 1 
age_55to64 2,269,061 26.288% 0.440 0 1 
male 2,269,061 47.061% 0.499 0 1 
white 2,269,061 81.869% 0.385 0 1 
black 2,269,061 6.496% 0.246 0 1 
other 2,269,061 11.635% 0.321 0 1 
less_than_high_school 2,269,061 11.635% 0.321 0 1 
high_school 2,269,061 23.156% 0.422 0 1 
some_college 2,269,061 28.025% 0.449 0 1 
bachelor_and_above 2,269,061 44.588% 0.497 0 1 
not_in_labor_force 2,269,061 17.095% 0.376 0 1 
employed 2,269,061 77.861% 0.415 0 1 
not_employed 2,269,061 5.044% 0.219 0 1 
less_than_25k 2,269,061 17.161% 0.377 0 1 
less_than_50k 2,269,061 24.758% 0.432 0 1 
less_than_75k 2,269,061 19.222% 0.394 0 1 
greater_than_75k 2,269,061 38.859% 0.487 0 1 
married 2,269,061 59.314% 0.491 0 1 
divorced_widowed_separated 2,269,061 19.174% 0.394 0 1 
never_married 2,269,061 21.512% 0.411 0 1 
nonsmoker 2,269,061 78.383% 0.412 0 1 
smoker 2,269,061 21.617% 0.412 0 1 
binge_drink 2,269,061 10.928% 0.312 0 1 
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Table 2. Mortality Regression – Full Sample  
  Column 1 Column 2 Column 3 Column 4 Column 5 
VARIABLES mortality mortality mortality mortality mortality 
npl 1.386 1.386 1.869**     
  (1.219) (1.219) (0.884)     
tpl 0.782 0.782   1.321*   
  (0.889) (0.889)   (0.660)   
gsl 0.261 0.261     0.948 
  (1.207) (1.207)     (0.952) 
pdmp -0.789 -0.789 -0.824 -0.834 -0.833 
  (0.827) (0.827) (0.845) (0.846) (0.854) 
pmcl 1.617 1.617 1.612 1.616 1.673 
  (1.810) (1.810) (1.820) (1.805) (1.811) 
age_18to24 -0.062 -0.062 -0.062 -0.062 -0.063 
  (0.039) (0.040) (0.041) (0.039) (0.040) 
age_25to34 -0.103*** -0.103*** -0.104*** -0.103*** -0.105*** 
  (0.035) (0.035) (0.036) (0.035) (0.036) 
age_35to44 -0.104*** -0.103*** -0.105*** -0.105*** -0.105*** 
  (0.027) (0.027) (0.027) (0.026) (0.027) 
age_45to54 -0.030* -0.029* -0.030* -0.029* -0.026* 
  (0.015) (0.015) (0.016) (0.016) (0.015) 
male -0.015* -0.014* -0.014 -0.014 -0.014* 
  (0.008) (0.008) (0.009) (0.009) (0.008) 
black 0.007 0.006 0.006 0.007 0.014 
  (0.061) (0.061) (0.065) (0.064) (0.063) 
other -0.057 -0.056 -0.056 -0.056 -0.052 
  (0.037) (0.038) (0.037) (0.038) (0.038) 
high_school -0.004 -0.004 -0.004 -0.003 -0.003 
  (0.017) (0.017) (0.017) (0.018) (0.018) 
some_college 0.027 0.028 0.029 0.028 0.029 
  (0.019) (0.020) (0.019) (0.019) (0.020) 
bachelor_and_above 0.032 0.032 0.034 0.032 0.036 
  (0.029) (0.030) (0.029) (0.030) (0.031) 
employed 0.010 0.010 0.011 0.010 0.011 
  (0.014) (0.014) (0.014) (0.014) (0.014) 
not_employed -0.004 -0.005 -0.004 -0.007 -0.007 
  (0.019) (0.018) (0.018) (0.020) (0.019) 
less_than_25k 0.066* 0.066* 0.064* 0.071** 0.069** 
  (0.034) (0.033) (0.034) (0.034) (0.034) 
less_than_50k 0.039 0.039 0.038 0.043* 0.041* 
  (0.024) (0.024) (0.023) (0.024) (0.024) 
less_than_75k 0.014 0.014 0.014 0.015 0.014 
  (0.019) (0.019) (0.018) (0.018) (0.019) 
divorced_widowed_separated -0.021** -0.021** -0.020** -0.023** -0.022** 
  (0.010) (0.010) (0.010) (0.011) (0.011) 
never_married -0.044** -0.044** -0.043** -0.047*** -0.045** 
  (0.017) (0.017) (0.017) (0.017) (0.017) 
smoker -0.002   -0.002 -0.002 -0.003 
  (0.010)   (0.010) (0.010) (0.009) 
binge_drink 0.008   0.009 0.010 0.009 
  (0.008)   (0.008) (0.008) (0.008) 
Observations 2194709 2194709 2194709 2194709 2194709 
R-squared 0.734 0.734 0.732 0.731 0.730 
33 
 
Table 3. Admissions Regression – Full Sample 
  Column 1 Column 2 Column 3 Column 4 Column 5 
VARIABLES admissions admissions admissions admissions admissions 
  all no drugs npl only tpl only gsl only 
npl 33.137** 33.137** 29.246*     
  (14.682) (14.682) (15.096)     
tpl 5.166 5.166   7.524   
  (13.463) (13.463)   (13.173)   
gsl -16.042 -16.041     -7.715 
  (15.262) (15.262)     (14.409) 
pdmp 12.649 12.650 13.293 12.616 11.958 
  (12.213) (12.214) (12.654) (12.673) (12.569) 
pmcl -26.955* -26.957* -26.122* -25.449* -25.618* 
  (13.771) (13.772) (13.592) (13.704) (13.847) 
age_18to24 -1.221** -1.204** -1.242** -1.278** -1.275** 
  (0.488) (0.491) (0.502) (0.524) (0.515) 
age_25to34 -1.228*** -1.196*** -1.240*** -1.250*** -1.257*** 
  (0.396) (0.398) (0.409) (0.418) (0.413) 
age_35to44 -1.167*** -1.143*** -1.144*** -1.164*** -1.192*** 
  (0.330) (0.328) (0.332) (0.338) (0.344) 
age_45to54 -0.458** -0.441** -0.421** -0.399* -0.412* 
  (0.203) (0.202) (0.208) (0.213) (0.208) 
male -0.265 -0.255 -0.275 -0.271 -0.263 
  (0.176) (0.174) (0.171) (0.173) (0.178) 
black 0.489 0.477 0.580 0.629 0.620 
  (0.671) (0.672) (0.758) (0.770) (0.717) 
other -0.447 -0.456 -0.431 -0.423 -0.398 
  (0.499) (0.503) (0.497) (0.512) (0.499) 
high_school -0.095 -0.125 -0.087 -0.067 -0.071 
  (0.249) (0.257) (0.249) (0.253) (0.249) 
some_college 0.058 0.012 0.052 0.041 0.052 
  (0.264) (0.282) (0.260) (0.261) (0.270) 
bachelor_and_above 0.133 0.058 0.150 0.137 0.161 
  (0.375) (0.407) (0.395) (0.393) (0.405) 
employed 0.157 0.156 0.158 0.150 0.166 
  (0.178) (0.178) (0.174) (0.174) (0.173) 
not_employed 0.039 0.059 0.046 -0.010 -0.014 
  (0.222) (0.226) (0.220) (0.229) (0.227) 
less_than_25k -0.558 -0.520 -0.541 -0.475 -0.522 
  (0.486) (0.474) (0.526) (0.522) (0.531) 
less_than_50k -0.303 -0.286 -0.299 -0.232 -0.249 
  (0.336) (0.332) (0.350) (0.358) (0.356) 
less_than_75k -0.240 -0.234 -0.243 -0.230 -0.241 
  (0.178) (0.179) (0.181) (0.178) (0.180) 
divorced_widowed_separated 0.024 0.052 0.016 -0.025 -0.015 
  (0.204) (0.219) (0.212) (0.219) (0.217) 
never_married -0.052 -0.033 -0.040 -0.093 -0.083 
  (0.241) (0.243) (0.247) (0.258) (0.253) 
smoker 0.258   0.234 0.241 0.258 
  (0.191)   (0.198) (0.202) (0.192) 
binge_drink 0.153   0.129 0.145 0.160 
  (0.130)   (0.128) (0.125) (0.127) 
Constant 103.666*** 103.765*** 102.452*** 103.261*** 103.971*** 
  (9.723) (9.688) (9.683) (9.580) (9.758) 
Observations 1827853 1827853 1827853 1827853 1827853 
R-squared 0.832 0.832 0.831 0.829 0.829 
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Table 4. Mortality Regression – Age Subsample Analysis 
  Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 
VARIABLES mortality  mortality mortality mortality mortality mortality 
  age 35-44 age 45-54 age 35-44 age 45-54 age 35-44 age 45-54 
npl 1.869** 1.869**         
  (0.884) (0.884)         
tpl     1.321* 1.321*     
      (0.660) (0.660)     
gsl         0.948 0.949 
          (0.953) (0.953) 
              
Observations 2194709 2194709 2194709 2194709 2194709 2194709 
R-squared 0.732 0.732 0.731 0.731 0.730 0.730 
Robust standard  
errors in 
parentheses             
*** p<0.01,  
** p<0.05,  
* p<0.1             
Notes: Only results for policy variables of interest are given. Complete results can be accessed 
upon request.  
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Table 5. Mortality Regression – Annual Household Income and Education Level 
Subsample Analysis 
 
  Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 
VARIABLES mortality mortality mortality mortality mortality mortality 
  Annual 
Household 
Income 
<$25k 
Annual 
Household 
Income 
<$25k 
Annual 
Household 
Income 
<$25k 
Education 
<bachelors 
Education 
<bachelors 
Education 
<bachelors 
npl 1.869**     1.869**     
  (0.884)     (0.884)     
tpl   1.321*     1.321*   
    (0.660)     (0.660)   
gsl     0.949     0.948 
      (0.953)     (0.952) 
              
Observations 2194709 2194709 2194709 2194709 2194709 2194709 
R-squared 0.732 0.731 0.730 0.732 0.731 0.730 
Robust standard  
errors in 
parentheses             
*** p<0.01,  
** p<0.05,  
* p<0.1             
Notes: Only results for policy variables of interest are given. Complete results can be accessed 
upon request.  
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Table 6. Admissions Regression – Age Subsample Analysis 
  Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 
VARIABLES admissions admissions admissions admissions admissions admissions 
  age 35-44 age 45-54 age 35-44 age 45-54 age 35-44 age 45-54 
npl 29.250* 29.252*         
  (15.099) (15.099)         
tpl     7.527 7.529     
      (13.174) (13.174)     
gsl         -7.716 -7.712 
          (14.412) (14.413) 
              
Observations 1827853 1827853 1827853 1827853 1827853 1827853 
R-squared 0.831 0.831 0.829 0.829 0.829 0.829 
Robust standard  
errors in 
parentheses             
*** p<0.01,  
** p<0.05,  
* p<0.1             
Notes: Only results for policy variables of interest are given. Complete results can be accessed 
upon request.  
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Table 7. Admissions Regression – Annual Household Income and Education Level 
Subsample Analysis 
 
  Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 
VARIABLES admissions admissions admissions admissions admissions admissions 
  Annual 
Houeshold 
Income 
<$25k 
Annual 
Houeshold 
Income 
<$25k 
Annual 
Houeshold 
Income 
<$25k 
Education
<bachelors 
Education
<bachelors 
Education
<bachelors 
npl 29.245*     29.246*     
  (15.097)     (15.097)     
tpl   7.525     7.525   
    (13.173)     (13.173)   
gsl     -7.715     -7.715 
      (14.409)     (14.409) 
              
Observations 1827853 1827853 1827853 1827853 1827853 1827853 
R-squared 0.831 0.829 0.829 0.831 0.829 0.829 
Robust standard 
errors in 
parentheses             
*** p<0.01,  
** p<0.05,  
* p<0.1             
Notes: Only results for policy variables of interest are given. Complete results can be accessed 
upon request.  
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APPENDIX 1 
Notes: The results show increasing trends of drug overdose death rates from 1999 through 2017. 
2017 rates were significantly higher for age groups 25-34, 35-44, and 45-54 than for age 
groups15-24, 55-64, and 65 and over (p < 0.05).  
Source: Data is from the NCHS, National Vital Statistics System, Mortality (Drug, 2018). 
 
Figure 1. Drug overdose death rates, by selected age group: United States, 1999-2017 
